{
  "docId": "019de076-39d2-7099-ad19-065ffc77ed59",
  "docSlug": "e110bee9f1b318f547399ddf66ee5ee3",
  "documentTitle": "Exscientia | Results Presentation Deck | 24 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 24,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a human anatomy diagram to map specific patient counts to disease locations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-39d2-7099-ad19-065ffc77ed59/8",
  "deckHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59",
  "deckJsonHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59.json",
  "deckAnchorHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.135,
        "w": 0.212,
        "x": 0.418,
        "y": 0.268
      },
      "kind": "callout",
      "text": "Brain metastases develop in ~50% of SCLC patients; '539, a brain penetrant molecule, may target brain metastases as well as peripheral disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b55c8ae8-cab5-446a-9997-f3021aa0f278",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.76,
        "w": 0.37,
        "x": 0.287,
        "y": 0.237
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bec56227-0904-4966-9959-84e4fe46d8e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "metric",
      "text": "28K Small-cell Lung Cancer Extensive Disease (Stage III / IV)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "140175f2-7745-4493-8c59-e8d69028494a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.68,
        "y": 0.47
      },
      "kind": "metric",
      "text": "~45K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23bb5b48-6596-45ad-8318-c407704ca6b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "metric",
      "text": "17K Acute Myeloid Leukaemia",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5042b90b-ff26-46f9-b46a-47cdf801f17a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Covers all indications currently being prioritised for IND/CTA-enabling studies. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; 1) Li et al. Int J Gen Med, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ddb322e-ed83-4d79-9b3c-a6e0e46ca240",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for planned patient sub-groups",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82eebd6e-c2b7-4d92-8307-5db5e87505b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "LSD1: '539 IND-enabling studies complete",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2e9b411-c174-4077-9bc4-9ef71d3169ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 4,
      "beatId": "7d3d7752-d9ec-4ba0-921e-c4049dd71ceb",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The document presents various evidence, including data and results, to support its claims and pipeline advancement",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "8341406f-e753-49e5-aaa2-5cfaa5dad183",
      "evidence": "The document presents a logical chain of events, from the platform to pipeline advancement",
      "position": 0,
      "objective": "How does Exscientia's AI-driven platform drive pipeline advancement",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}